Core Insights - Revolution Medicines, Inc. (RVMD) is experiencing significant stock volatility in early 2026, driven by takeover speculation from major players, particularly Merck (MRK) [1] Company Overview - Revolution Medicines is positioned in the biotechnology sector, focusing on innovative drug development with unique mechanisms of action and first-in-class therapies [1] - The company aims to reshape treatment paradigms through its platform technologies [1] Analyst Background - The analyst has a Master's degree in Cell Biology and extensive experience in drug discovery, which informs their investment analysis in the biotech sector [1] - The analyst has been active in the investment space for five years, with a focus on biotech equity analysis for the past four years [1] Investment Focus - The analysis emphasizes evaluating the science behind drug candidates, competitive landscape, clinical trial design, and market opportunities while balancing financial fundamentals and valuation [1] - The goal is to provide insights that help investors understand both opportunities and risks in the biotech sector, which can yield significant returns through breakthrough science [1]

Market Overview - U.S. stock futures are lower, with Dow futures down approximately 0.1% on Monday [1] Revolution Medicines Inc - Shares of Revolution Medicines Inc (NASDAQ:RVMD) fell 26.1% to $87.02 in pre-market trading following reports that Merck (NYSE:MRK) is no longer in talks to acquire the company [1] Erasca Inc - Erasca Inc (NASDAQ:ERAS) experienced a decline of 11.5%, trading at $8.82 in pre-market after announcing the closing of an upsized public offering of common stock [2] BlackRock TCP Capital Corp - BlackRock TCP Capital Corp (NASDAQ:TCPC) saw a decrease of 8.7%, trading at $5.35 in pre-market [2] Ambitions Enterprise Management Co LLC - Ambitions Enterprise Management Co LLC (NASDAQ:AHMA) dipped 7.9% to $28.30 in pre-market trading after a 17% drop on Friday, despite reporting a year-over-year increase in H1 EPS results [2] Regencell Bioscience Holdings Ltd - Regencell Bioscience Holdings Ltd (NASDAQ:RGC) fell 6% to $29.52 in pre-market trading after a 2% gain on Friday [2] Sierra Bancorp - Sierra Bancorp (NASDAQ:BSRR) declined 5.8% to $33.02 in pre-market trading [2] Forward Industries Inc - Forward Industries Inc (NASDAQ:FWDI) declined 4.6% to $7.46 in pre-market trading [2] Argo Blockchain PLC - Argo Blockchain PLC – ADR (NASDAQ:ARBK) fell 3.8% to $4.20 in pre-market trading [2] MINISO Group Holding Ltd - MINISO Group Holding Ltd – ADR (NYSE:MNSO) declined 3.6% to $19.12 in pre-market trading [2] Corvus Pharmaceuticals Inc - Corvus Pharmaceuticals Inc (NASDAQ:CRVS) fell 3.2% to $24.17 in pre-market trading after announcing the closing of an upsized public offering of common stock, generating gross proceeds of approximately $201 million [2]

Group 1 - Erasca Inc. is a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers [4] - The company is conducting two Phase 1 trials with its lead drug ERAS-0015 in patients with RAS-mutant solid tumors, with initial data expected in 2026 [4] - Erasca recently priced its upsized public offering of 22.5 million shares at $10.00 per share, resulting in gross proceeds of $225 million [4][5] Group 2 - Revolution Medicines is a late-stage clinical oncology company developing targeted therapies for RAS-addicted cancers, with a pipeline that includes RAS(ON) inhibitors [3] - The company was valued at approximately $30 billion during acquisition discussions with Merck, which ultimately ended due to disagreements on valuation [2] - Merck's decision reflects its disciplined approach to deal size despite interest in high-growth oncology assets [2]

Merck & Co., Inc. (NYSE:MRK) has reportedly ended discussions to acquire cancer drug developer Revolution Medicines, Inc. (NASDAQ:RVMD) after the two sides disagreed on valuation.Earlier in January, the Financial Times reported that Merck is reportedly in talks to acquire Revolution Medicines in a deal potentially valued at between $28 billion and $32 billion.The talks had valued Revolution Medicines at roughly $30 billion. Citing people familiar with the matter, the Wall Street Journal report on Sunday sig ...

| RVMD Revolution Medicines | | | | --- | --- | --- | | 117.630 ↓ -1.180 -0.99% | | 收盘价 01/23 16:00 美东 | | 90.580 ↓ -27.050 -23.00% | | 盘前价 01/26 04:08 美东 | | 三 四 四 图 图 图 中 白选 | | ● 快捷交易 | | 最高价 120.630 | 开盘价 118.400 | 成交量 252.24万 | | 最低价 117.590 | 昨收价 118.810 | 成交额 3亿 | | 平均价 118.797 | 市盈率ITM 亏损 | 总市值 227.4亿(…) | | 振 幅 2.56% | 市盈率(静) 亏损 | 总股本 1.93亿 | | 换手率 1.45% | 市净率 14.240 | 流通值 204.63亿 | | 52周最高 124.490 | 委 比 -99.56% | 流通股 1.74亿 | | 52周最低 29.170 | 量 比 0.63 | 包 主 1股 | | 历史最高 124.490 | 股息TIM -- | | | 历史最低 ...

Group 1 - Merck has ceased discussions regarding the acquisition of Revolution Medicines, which was previously valued at approximately $30 billion [1] - Negotiations cooled due to a lack of agreement on price, but there is potential for talks to resume or for other buyers to emerge [1] - Revolution Medicines is expected to release trial data for its pancreatic and colorectal cancer drug candidates in the first half of this year [1] Group 2 - Merck's CEO stated that the company is primarily focused on transactions under $15 billion but is open to larger acquisitions while maintaining a cautious approach [2] - Revolution Medicines is developing drugs targeting RAS-driven cancers, which have been challenging to treat due to technical difficulties [2] - If Revolution's pancreatic cancer drug candidate proves safe and effective, it could achieve global sales of $10 billion by 2035, dominating the treatment of this disease [2] Group 3 - The cancer treatment market is one of the most important and profitable sectors in the pharmaceutical industry, with global sales of cancer drugs exceeding $240 billion last year [2]

默沙东正寻找能增强其治疗产品组合的交易，以应对专利到期带来的损失，预计未来五年内专利到期将 导致其销售额减少180亿美元。Revolution目前有多种化合物正在研发中，其一种用于治疗转移性胰腺癌 的主导药物的关键性研究结果，预计于今年夏季公布。 美股频道更多独家策划、专家专栏，免费查阅>> 1月26日，据华尔街日报，默沙东据报已终止收购生物技术公司Revolution Medicines的谈判，原因是双 方未能就价格达成协议。消息人士指，这笔交易对Revolution的估值可能约为300亿美元，并补充称谈判 可能会重启，或可能会出现其他竞购者。 责任编辑：栎树 ...

Group 1 - Merck (MRK.US) has halted acquisition talks with Revolution Medicines (RVMD.US) due to disagreements over the purchase price, which was estimated to value Revolution Medicines at around $30 billion [1] - Merck is seeking to strengthen its treatment portfolio to address an anticipated $18 billion loss in sales over the next five years due to patent expirations, particularly with its key cancer drug Keytruda losing patent protection by the end of this decade [1] - The potential acquisition could have provided Merck with Revolution Medicines' experimental drug Daraxonrasib, which is a key asset for the company [1][2] Group 2 - Daraxonrasib (RMC-6236) is an oral targeted drug that acts as a multi-selective inhibitor of RAS, aimed at treating cancers driven by RAS gene mutations [2] - The drug targets common oncogenic RAS mutations, including G12X, G13X, and Q61X, which are significant drivers of major cancers such as pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC) [2] - Daraxonrasib is currently being evaluated in four global Phase 3 clinical trials, including three studies focused on PDAC and one on locally advanced or metastatic RAS-mutant NSCLC, with key results expected to be announced this summer [2][3] Group 3 - The RASolute304 clinical trial, which is a global, open-label Phase 3 study, aims to assess the safety and efficacy of Daraxonrasib in resectable PDAC patients who have undergone surgery and chemotherapy [3] - The trial plans to enroll approximately 500 patients with oncogenic RAS mutations who have completed tumor resection and perioperative chemotherapy [3] - Industry research indicates that the pancreatic cancer treatment market could expand tenfold to over $3 billion by 2035, driven by Daraxonrasib, which is expected to receive FDA approval by 2026 [3]

智通财经APP获悉，据知情人士透露，由于双方未能就收购价格达成一致，默沙东(MRK.US)已停止收 购生物技术公司Revolution Medicines(RVMD.US)的谈判。 据悉，Revolution Medicines正在研发的泛RAS抑制剂RMC-6236(通用名为Daraxonrasib)是该公司拥有的 关键资产。Daraxonrasib这款前沿药物是一种口服靶向药、一种直接作用的RAS(ON)多选择性抑制剂， 用于治疗由RAS基因突变驱动的癌症。它直接作用于处于激活状态的RAS蛋白，阻断RAS与下游信号蛋 白的结合，从而抑制RAS信号通路的持续激活，减缓肿瘤细胞的生长和增殖。Daraxonrasib靶向常见的 致癌性RAS突变，包括G12X、G13X和Q61X突变，这些突变是胰腺导管腺癌(PDAC)、非小细胞肺癌 (NSCLC)和结直肠癌(CRC)等主要癌种的重要驱动因素。 目前，Daraxonrasib正在四项全球3期临床试验中接受评估，其中包括三项针对胰腺导管腺癌(PDAC)的 研究，以及一项针对局部晚期或转移性RAS突变非小细胞肺癌(NSCLC)的研究。关键研究结果预计将于 今年夏季公布 ...

Core Viewpoint - Merck has ceased discussions regarding the acquisition of Revolution Medicines, a company focused on developing cancer drugs, as reported by the Wall Street Journal [1] Company Summary - Merck is a major player in the pharmaceutical industry, known for its extensive portfolio in drug development, including oncology [1] - Revolution Medicines specializes in innovative cancer therapies, indicating a strategic interest in the oncology sector [1] Industry Summary - The oncology drug market continues to attract significant attention from large pharmaceutical companies, highlighting the competitive landscape in cancer treatment development [1] - The cessation of acquisition talks may reflect broader market dynamics or strategic realignments within Merck and its investment priorities in the oncology space [1]